CTSL and severe acute respiratory syndrome: Both compounds display a pronounced inhibitory effect against SARS-CoV infection (fusion) in HEK293T cells (IC50 teicoplanin: 3.76 ± 1.1 μM; dalbavancin; 9.64 ± 1.3 μM) but not against free cathepsin L enzyme (IC50 > 200 μM) [45].